Post by icemandios on Jan 3, 2022 13:34:36 GMT
Phio Pharmaceuticals Scheduled to Participate in the H.C. Wainwright Virtual BioConnect 2022 Conference
PR Newswire
MARLBOROUGH, Mass. , Jan. 3, 2022 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today announced that its Chief Executive Officer, Dr. Gerrit Dispersyn , will participate in the H.C. Wainwright Virtual BioConnect 2022 Conference, which is being held on January 10 – 13, 2022.
Logo - mma.prnewswire.com/media/786567/Phio_Pharmaceuticals_Logo.jpg
H.C. Wainwright Virtual BioConnect 2022 Conference:
Date: January 10 – 13, 2022
Time: Presentation will be available on-demand as of 7 a.m. EST on January 10th
Webcast: Register Here
Interested parties may access the webcast presentation from the H.C. Wainwright Virtual BioConnect 2022 Conference through the "Investors – Events and Presentations" section of the Company's website . The webcast will be archived and available on the Company's website for 90 days.
About Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Corp. (Nasdaq: PHIO) is a biotechnology company developing the next generation of immuno-oncology therapeutics based on its self-delivering RNAi (INTASYL™) therapeutic platform. The Company's efforts are focused on silencing tumor-induced suppression of the immune system through its proprietary INTASYL platform with utility in immune cells and the tumor micro-environment. Our goal is to develop powerful INTASYL therapeutic compounds that can weaponize immune effector cells to overcome tumor immune escape, thereby providing patients a powerful new treatment option that goes beyond current treatment modalities. For additional information, visit the Company's website, www.phiopharma.com .
PR Newswire
MARLBOROUGH, Mass. , Jan. 3, 2022 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today announced that its Chief Executive Officer, Dr. Gerrit Dispersyn , will participate in the H.C. Wainwright Virtual BioConnect 2022 Conference, which is being held on January 10 – 13, 2022.
Logo - mma.prnewswire.com/media/786567/Phio_Pharmaceuticals_Logo.jpg
H.C. Wainwright Virtual BioConnect 2022 Conference:
Date: January 10 – 13, 2022
Time: Presentation will be available on-demand as of 7 a.m. EST on January 10th
Webcast: Register Here
Interested parties may access the webcast presentation from the H.C. Wainwright Virtual BioConnect 2022 Conference through the "Investors – Events and Presentations" section of the Company's website . The webcast will be archived and available on the Company's website for 90 days.
About Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Corp. (Nasdaq: PHIO) is a biotechnology company developing the next generation of immuno-oncology therapeutics based on its self-delivering RNAi (INTASYL™) therapeutic platform. The Company's efforts are focused on silencing tumor-induced suppression of the immune system through its proprietary INTASYL platform with utility in immune cells and the tumor micro-environment. Our goal is to develop powerful INTASYL therapeutic compounds that can weaponize immune effector cells to overcome tumor immune escape, thereby providing patients a powerful new treatment option that goes beyond current treatment modalities. For additional information, visit the Company's website, www.phiopharma.com .